Acetate PET useful for assessing response of prostate cancer bone metastases
Published
31 March 2011
| Article by Clinical Nuclear Medicine 2011
| Tags:
positron-emission-tomography-(pet),
prostate-cancer,
bone-metastases,
c11-acetate-(acetate),
f-18-fluorodeoxyglucose-(fdg),
response.
Acetate PET useful for assessing response of prostate cancer bone metastases
Abstract
Purpose of the Report This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET.
To read the full article, please register for GetInsideHealth below.
Register for GetInsideHealth
GetInsideHealth is free and registration is easy. You'll have exclusive access to a huge range of industry-specific features and news reports from some of the most respected commentators on health and well-being, with an emphasis on the latest developments and innovations in cardiology, oncology, radiology, and OBGYN.
Please fill in the form below to register.
Already Registered?
Please login using
form at top of page
Fields with an asterisk (*) are mandatory
About you
Login information
Newsletter
Additional information